A randomized open-label study comparing the docetaxel plus prednisone regimen versus mitoxantrone plus prednisone regimen for metastatic hormone refractory prostate cancer in Chinese population
单位：[1]Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China[2]Second Mil Med Univ, Changhai Hosp, Shanghai, Peoples R China[3]Sichuan Univ, West China Hosp, West China Sch Med, Chengdu 610064, Peoples R China四川大学华西医院[4]Chinese PLA, Sch Med, Chinese PLA Gen Hosp, Beijing, Peoples R China[5]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan 430074, Peoples R China华中科技大学同济医学院附属同济医院[6]Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai 200030, Peoples R China[7]Nanjing Med Univ, Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China江苏省人民医院[8]Peking Univ, Beijing Canc Hosp, Beijing 100871, Peoples R China[9]Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China首都医科大学附属北京友谊医院[10]Peking Univ, Shougang Hosp, Beijing 100871, Peoples R China
第一作者单位：[1]Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China
推荐引用方式(GB/T 7714)：
Ye D.,Sun Y. H.,Wei Q.,et al.A randomized open-label study comparing the docetaxel plus prednisone regimen versus mitoxantrone plus prednisone regimen for metastatic hormone refractory prostate cancer in Chinese population[J].EUROPEAN JOURNAL of CANCER.2013,49:S706-S706.
APA：
Ye, D.,Sun, Y. H.,Wei, Q.,Yao, X.,Ye, Z. Q....&Na, Y. Q..(2013).A randomized open-label study comparing the docetaxel plus prednisone regimen versus mitoxantrone plus prednisone regimen for metastatic hormone refractory prostate cancer in Chinese population.EUROPEAN JOURNAL of CANCER,49,
MLA：
Ye, D.,et al."A randomized open-label study comparing the docetaxel plus prednisone regimen versus mitoxantrone plus prednisone regimen for metastatic hormone refractory prostate cancer in Chinese population".EUROPEAN JOURNAL of CANCER 49.(2013):S706-S706
医学